Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder

J Psychiatr Res. 2022 May:149:367-373. doi: 10.1016/j.jpsychires.2021.11.025. Epub 2021 Nov 17.

Abstract

Exacerbation of symptoms of obsessive-compulsive disorder (OCD) during COVID-19 or new onset of the OCD symptoms resulting from COVID-19 infection is an understudied area of research. It is possible that increased proinflammatory immune status is associated with the onset of obsessive-compulsive symptoms in patients with COVID-19 and that targeted anti-inflammatory treatments for COVID-19 infection can mitigate the new onset of Obsessive-Compulsive (OC) spectrum symptoms. In this review, we cover OCD pathogenesis as related to COVID-19, summarize the impact of cytokines on behavior, and suggest that anti-cytokine treatments can help mitigate post-COVID-19 and new onset of the OC symptoms.

Keywords: COVID-19; Neuroinflammation; OCD; Obsessive-compulsive disorder.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / complications
  • Humans
  • Neuroinflammatory Diseases
  • Obsessive-Compulsive Disorder* / diagnosis